Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
Marie-Léa Gauci(Inserm), Célèste Lebbé(Inserm), Brigitte Dréno(Inserm), Astrid Blom(Université de Versailles Saint-Quentin-en-Yvelines), Nicole W.J. Kelleners-Smeets(Maastricht University Medical Centre), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), Fábio Gomes(Cancer Research UK), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Jet Company (Czechia)), Catherine Harwood(Queen Mary University of London), Axel Hauschild(Kiel University), Josep Malvehy(Instituto de Salud Carlos III), Cynthia Aristei(University of Perugia), Christoph Höeller(Medical University of Vienna), Maria Concetta Fargnoli(University of L'Aquila), Aimilios Lallas(Aristotle University of Thessaloniki), Jürgen C. Becker(German Cancer Research Center), Paul Lorigan(University of Manchester), V. del Mármol(Université Libre de Bruxelles), Alexander C. J. van Akkooi(The University of Sydney), Iris Zalaudek(University of Trieste), Ana‐Maria Forsea(Carol Davila University of Medicine and Pharmacy), Alexander J. Stratigos(National and Kapodistrian University of Athens), Ketty Peris(Università Cattolica del Sacro Cuore), Giovanni Pellacani(Sapienza University of Rome), Jean-Jacques Grob(Aix-Marseille Université), Claus Garbe(University Children's Hospital Tübingen)
Cited by 173
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k